logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Deferiprone for transfusional iron overload in sickle cell disease and other anaemias – First Line

< Back

Deferiprone for transfusional iron overload in sickle cell disease and other anaemias – First Line

Drugs

Haematology and Blood Products

December 2020


Deferiprone is in clinical development for patients with sickle-cell disorder (SCD) and other anaemias that are suffering from iron overload due to frequent transfusions to increase their red blood cell count. SCD is a group of inherited disorders where the red blood cells become hard and sticky and look like a C-shaped farm tool called a “sickle”. The sickle red blood cells die early, and patients often require blood transfusions. Iron overload is an effect of frequent transfusions in SCD. Excess iron in the body can be toxic to major organs like the heart and liver.

Deferiprone is administered orally and can reduce iron overload by binding to it, forming a complex, which can then be excreted in the urine. This reduces iron levels in the body, preventing iron toxicity. If licensed, deferiprone would offer an additional first-line treatment for transfusional iron overload in sickle-cell disease and other anaemias.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts